Now Reading: Maharashtra FDA cancels Cipla Pune unit’s drug sale licence
-
01
Maharashtra FDA cancels Cipla Pune unit’s drug sale licence
The Maharashtra Food and Drug Administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding unit in Pune, citing serious irregularities in storage, packaging, and…
The Maharashtra Food and Drug Administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding unit in Pune, citing serious irregularities in storage, packaging, and recall procedures for Reactin Plus Tablets. The cancellation took effect on August 27, following an inspection of the company's warehouse in Wadki, Pune district.
During a June inspection, FDA officials found that packaging for Reactin Plus, a Schedule H prescription drug, carried an unauthorised claim describing it as an 'analgesic and antipyretic'. The regulator seized stock worth Rs 11.19 lakh. The FDA also found medicines stored on the floor, discrepancies between computerised and physical stock, and non-compliance with recall directions. FDA Commissioner Tukaram Mundhe said there would be zero tolerance on drug safety violations.
Cipla Pharma & Life Sciences has contested the order, stating the matter is sub judice. The company clarified that the order does not allege any concerns regarding the safety, quality, or efficacy of its products.
Indian Opinion Analysis
All four sources report the same facts with no discernible slant. Each leads with the licence cancellation, includes the Rs 11.19 lakh seizure, the storage deficiencies, the recall non-compliance, and Cipla's response that the matter is sub judice and product quality is not questioned. Commissioner Mundhe's zero-tolerance statement appears in every account. The uniform coverage suggests wire agency copy (PTI) as the common base. The next step: Cipla's judicial challenge will test whether the FDA's cancellation is upheld or modified.
Coverage: 4 sources, 4 neutral
Sources (4): economictimes.indiatimes.com (neutral report), thehindu.com (neutral report), ndtv.com (neutral report), livemint.com (neutral report)
This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry.
Updated: this story now draws on 4 sources.
